Rodrigo Koprovski Menguer1, Antônio Carlos Weston2, Helena Schmid3. 1. Diabetes and Obesity Education and Research Center and Obesity Treatment Center of Hospital Santa Casa de Misericórdia de Porto Alegre, Universidade Federal de Ciências da Saúde de Porto Alegre, Av. Independência, 78/701, Centro. 90020-160, Porto Alegre, RS, Brazil. rkmenguer@gmail.com. 2. Obesity Treatment Center, Hospital Santa Casa de Misericórdia de Porto Alegre, Av. Independência, 78/701, Centro. 90020-160, Porto Alegre, Rio Grande do Sul, Brazil. 3. Diabetes and Obesity Education and Research Center and Obesity Treatment Center of Hospital Santa Casa de Misericórdia de Porto Alegre, Universidade Federal de Ciências da Saúde de Porto Alegre, Av. Independência, 78/701, Centro. 90020-160, Porto Alegre, RS, Brazil.
Abstract
BACKGROUND: Morbid obesity is a state of insulin resistance combined with excess of visceral fat, which contributes to the development of metabolic syndrome (MetS). Nonsurgical treatment of obesity usually improves MetS, but there is no ultimate resolution and weight regain is common. Surgical options like Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) result in a significant and sustained weight loss accompanied by improvement of MetS. The aim of this study was to compare the weight loss and improvement of MetS parameters between degree II and III obese patients with MetS undergoing RYGB or SG in a period of 12 months. METHODS: Analysis of medical records of 102 patients diagnosed with MetS (63 undergoing RYGB and 39 undergoing SG) in a reference center (CTO ISCMPA) between 2010 and 2013. RESULTS: After 1-year follow-up, an excess weight loss (EWL) of 77.2 ± 22.5% and of 63.4 ± 20.1% (p = 0.033) was observed in the RYGB and SG groups, respectively. The rate of MetS resolution was very similar (87.3 and 84.6%, respectively; p = 0.971). The percentage of patients with type 2 diabetes was 3.3% for RYGB and 15.4% for SG (p = 0.025). Fasting blood glucose levels followed the same trend with mean values reaching 87.6 ± 16.9 mg/dl in the RYGB group and 97.7 ± 35.5 mg/dl in the group undergoing SG (p = 0.023). CONCLUSIONS: Among the patients studied, both surgical techniques were safe and effective for MetS resolution in 12 months. However, RYGB was more effective for EWL and improvement of some parameters related to glucose metabolism.
BACKGROUND: Morbid obesity is a state of insulin resistance combined with excess of visceral fat, which contributes to the development of metabolic syndrome (MetS). Nonsurgical treatment of obesity usually improves MetS, but there is no ultimate resolution and weight regain is common. Surgical options like Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) result in a significant and sustained weight loss accompanied by improvement of MetS. The aim of this study was to compare the weight loss and improvement of MetS parameters between degree II and III obesepatients with MetS undergoing RYGB or SG in a period of 12 months. METHODS: Analysis of medical records of 102 patients diagnosed with MetS (63 undergoing RYGB and 39 undergoing SG) in a reference center (CTO ISCMPA) between 2010 and 2013. RESULTS: After 1-year follow-up, an excess weight loss (EWL) of 77.2 ± 22.5% and of 63.4 ± 20.1% (p = 0.033) was observed in the RYGB and SG groups, respectively. The rate of MetS resolution was very similar (87.3 and 84.6%, respectively; p = 0.971). The percentage of patients with type 2 diabetes was 3.3% for RYGB and 15.4% for SG (p = 0.025). Fasting blood glucose levels followed the same trend with mean values reaching 87.6 ± 16.9 mg/dl in the RYGB group and 97.7 ± 35.5 mg/dl in the group undergoing SG (p = 0.023). CONCLUSIONS: Among the patients studied, both surgical techniques were safe and effective for MetS resolution in 12 months. However, RYGB was more effective for EWL and improvement of some parameters related to glucose metabolism.
Authors: Lars Sjöström; Markku Peltonen; Peter Jacobson; C David Sjöström; Kristjan Karason; Hans Wedel; Sofie Ahlin; Åsa Anveden; Calle Bengtsson; Gerd Bergmark; Claude Bouchard; Björn Carlsson; Sven Dahlgren; Jan Karlsson; Anna-Karin Lindroos; Hans Lönroth; Kristina Narbro; Ingmar Näslund; Torsten Olbers; Per-Arne Svensson; Lena M S Carlsson Journal: JAMA Date: 2012-01-04 Impact factor: 56.272
Authors: Helena Schmid; Claudio Fernando Goelzer Neto; Lisiane Stefani Dias; Antonio Carlos Weston; Marília Bittencourt Espíndola; Sergio Ricardo Pioner; Luiz Alberto De Carli Journal: Rev Assoc Med Bras (1992) Date: 2015 Mar-Apr Impact factor: 1.209
Authors: S K Malin; J Bena; B Abood; C E Pothier; D L Bhatt; S Nissen; S A Brethauer; P R Schauer; J P Kirwan; S R Kashyap Journal: Diabetes Obes Metab Date: 2014-09-14 Impact factor: 6.577
Authors: Priya Sumithran; Luke A Prendergast; Elizabeth Delbridge; Katrina Purcell; Arthur Shulkes; Adamandia Kriketos; Joseph Proietto Journal: N Engl J Med Date: 2011-10-27 Impact factor: 91.245
Authors: Mehmet Ertuğrul Kafalı; Mustafa Şahin; İlhan Ece; Fahrettin Acar; Hüseyin Yılmaz; Hüsnü Alptekin; Leyla Ateş Journal: Turk J Surg Date: 2017-09-01